Novartis Raises Profit Outlook Despite $1.9bn Writedown on Key Drug
The Swiss drugmaker adjusted its core operating income guidance to flat or low-single-digit growth after a trial failure triggered the impairment charge.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 2 articles since 27 Oct 2026. Quartz published first, on 27 October at 12:00 UTC; News Feed followed 2h 28m later. The most recent article, from News Feed, appeared on 27 October at 14:28 UTC.
Outlets reporting it: News Feed (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Novartis